Compared with IgG, toripalimab significantly increased tumor‐infiltrating CD4+ and CD8+ T cells and inhibited tumor cell proliferation, as indicated by the downregulation of Ki67 expression, while the RBPJL‐overexpressing group showed more infiltration in the presence of toripalimab. Here, CD4 is linked to neoplasm.